A clinical trial for another BET inhibitor, OTX015, a small molecule with a similar scaffold to JQ1, is also ongoing (ClinicalTrials.gov identifier: NCT02259114), demonstrating the great potential of such compounds for cancer therapies. Here, DNER is linked to cancer.